Evidence map›Paper›PMID 31907645›Full record

Trial reportCancer chemotherapy and pharmacology2020

A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.

Ya-Nan Liu, Jie Huang, Can Guo, Shuang Yang, Ling Ye, Shu-Ting Wu, Xing-Fei Zhang, Xiao-Yan Yang, Cui-Cui Han, Qi Pei and 3 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer chemotherapy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ya-Nan Liu *Clinical Trails Center of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jie Huang *Clinical Trails Center of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Can GuoClinical Trails Center of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Shuang YangClinical Trails Center of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ling YeClinical Trails Center of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Shu-Ting WuClinical Trails Center of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xing-Fei ZhangClinical Trails Center of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiao-Yan YangClinical Trails Center of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Cui-Cui HanQilu Pharmaceutical Co. Ltd, Jinan, Shangdong, China.
Qi PeiDepartment of Pharmacy of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Lu HuangDepartment of Pharmacy of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qing-Nan HeResearch Center for Drug Clinical Evaluation, Central South University, Changsha, Hunan, China. heqn2629@163.com.
Guo-Ping YangClinical Trails Center of the Third Xiangya Hospital, Central South University, Changsha, Hunan, China. ygp9880@126.com.ORCID http://orcid.org/0000-0001-5930-586X
Central South University · CNLuye Pharma (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis is the first study to compare the pharmacokinetics of QL1101, a proposed bevacizumab biosimilar, with Avastin

methodsIn this double-blind, single-dose, parallel-group study, healthy male subjects were randomized 1:1 to receive QL1101 or Avastin

resultsA total of 82 subjects were randomized to the following groups: 42 to QL1101 and 40 to Avastin

conclusionsThe study demonstrated the pharmacokinetic equivalence of QL1101 to Avastin

Indexed as

Administration, IntravenousAdolescentAdultAntineoplastic Agents, ImmunologicalArea Under CurveBevacizumabBiosimilar PharmaceuticalsDouble-Blind MethodHealthy VolunteersHumansMaleTherapeutic EquivalencyYoung AdultAntineoplastic Agents, ImmunologicalBevacizumabBiosimilar PharmaceuticalsBevacizumabBiosimilarImmunogenicityPharmacokineticsQL1101Safety

Identifiers

PMID31907645
PMCPMC7036053
OpenAlexW2998001174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.